Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.

本方案的主要目标是为爱泼斯坦-巴尔病毒（Epstein-Barr virus）相关疾病及恶性肿瘤受试者扩大他贝克莱塞尔（tabelecleucel）的可及范围，此类受试者无其他合适的治疗选择，且无法入组用于支持他贝克莱塞尔开发与注册的临床试验。